Healthcare entity
market-trends is the sole category represented across all 1 tracked stories. Giredestrant is most often covered alongside AstraZeneca, which appears in 1 of these 1 story. At 7, the average consequence score sits above the same-window beat average of 6.
Last mentioned: Mar 9, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
market-trends is the sole category represented across all 1 tracked stories. Giredestrant is most often covered alongside AstraZeneca, which appears in 1 of these 1 story. At 7, the average consequence score sits above the same-window beat average of 6. They are less corroborated than the beat average, carrying 4 original sources each against 4.1 for the same window. We currently track 1 Healthcare story that mention Giredestrant, all published on March 9, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 30 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Giredestrant. Shared-story counts are live from our verified record — not editorial picks.
Trial Failure Announced
Roche confirms the oral SERD candidate failed to meet primary endpoints; shares dip immediately.
Phase II Data Review
Earlier data had suggested potential efficacy, leading to high investor expectations for the Phase III results.
Combination Trials Launch
Roche expanded the program to include combination therapies with CDK4/6 inhibitors.
Roche's stock fell on March 9, 2026, following the failure of its oral breast cancer candidate in a key clinical trial. This setback complicates the Swiss pharmaceutical giant's efforts to modernize its oncology portfolio and compete in the lucrative oral SERD market.
Source: northweststar.com.au · hardenexpress.com.au
Giredestrant is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
